News & Research

Hyperbaric Oxygen Therapy has been used for the better part of two centuries. Search our  arhives below for past HBOT news and research or scroll down for the latest.

The Latest HBOT News & Research

Clinical Trial – Dexmedetomidine for Sedation in Total Knee Replacements

Dexmedetomidine has demonstrated benefits both in sedation, and post-operative pain control,
with less respiratory depression than other common sedatives. Traditionally, dexmedetomidine
has been used with a large loading dose and infusion, which has been known to cause
dose-dependent negative side-effects (Abdallah et al., 2013). Single dose dexmedetomidine
produces less negative side-effects, but still effective sedation and reduced post-operative
pain (Jung et al., 2013). There is evidence for its benefits with general anesthesia but only
a few studies exist investigating its benefits when administered for sedation purposes with
spinal anesthesia, and no studies primarily examine post-operative opioid consumption. The
investigators hypothesize that single dose dexmedetomidine for procedural sedation will
reduce opioid consumption after total knee arthroplasty (TKA).

Hyperbaric oxygen in chronic traumatic brain injury: oxygen, pressure, and gene therapy.

Hyperbaric oxygen therapy is a treatment for wounds in any location and of any duration that has been misunderstood for 353 years. Since 2008 it has been applied to the persistent post-concussion syndrome of mild traumatic brain injury by civilian and later military researchers with apparent conflicting results. The civilian studies are positive and the military-funded studies are a mixture of misinterpreted positive data, indeterminate data, and negative data. This has confused the medical, academic, and lay communities. The source of the confusion is a fundamental misunderstanding of the definition, principles, and mechanisms of action of hyperbaric oxygen therapy. This article argues that the traditional definition of hyperbaric oxygen therapy is arbitrary. The article establishes a scientific definition of hyperbaric oxygen therapy as a wound-healing therapy of combined increased atmospheric pressure and pressure of oxygen over ambient atmospheric pressure and pressure of oxygen whose main mechanisms of action are gene-mediated. Hyperbaric oxygen therapy exerts its wound-healing effects by expression and suppression of thousands of genes. The dominant gene actions are upregulation of trophic and anti-inflammatory genes and down-regulation of pro-inflammatory and apoptotic genes. The combination of genes affected depends on the different combinations of total pressure and pressure of oxygen. Understanding that hyperbaric oxygen therapy is a pressure and oxygen dose-dependent gene therapy allows for reconciliation of the conflicting TBI study results as outcomes of different doses of pressure and oxygen.

Clinical Trial – Spinal Morphine Provides an Effective Pain Control in Patients Undergoing Transurethral Resection of Prostate Gland

Pain after transurethral resection of prostate is considered mild to moderate severity from
detrusor muscle spasm and traction from urinary catheter. Numerous pain relieve methods have
been studied including spinal opioids, spinal anesthesia with local anesthetic and
dexmedetomidine, periprostatic nerve blockade with bupivacaine and mixing of prilocaine with
distilled water irrigation while undergoing a procedure. Most of patients having this
procedure are in elderly period, thus many anesthetists avoided spinal morphine which may
cause respiratory depressant effect postoperatively. Although previous studies showed
effectiveness of spinal morphine 25-200 mcg, some patients suffered from neuraxial opioid
side effects.

The aim of this study is to demonstrate efficacy of local anesthetic with intrathecal
morphine 50 mcg providing pain relieve after transurethral resection of prostate compare to
spinal anesthesia with sole local anesthetic.

Clinical Trial – Hyperbaric Oxygen Therapy Registry

The purpose of the Hyperbaric Oxygen Therapy Registry (HBOTR) is to provide real world
patient outcome and side effect information from electronic health records submitted to a
specialty specific hyperbaric registry as part of "Stage 2 of Meaningful Use," including data
provided to meet PQRS requirements via the registry’s QCDR mission.

Goals include understanding the value of HBOT among patients treated for a variety of
conditions in relation to the frequency and severity of HBOT side effects. While randomized,
controlled trials can establish the efficacy of treatments like HBOT, because they routinely
exclude patients with co-morbid conditions common to those patients seen in usual clinical
practice, the results of RCTs are usually non-generalizable. Real world data can be used to
better understand the effectiveness of HBOT among typical patients, as well as the risks
associated with treatment.